RICHMOND, Va., June 16, 2022 /PRNewswire/ -- Indivior PLC (LON:
INDV) announces the appointment of Nina
DeLorenzo as Chief Global Impact Officer. DeLorenzo will
serve on the Executive Committee and report to Indivior Chief
Executive Officer Mark Crossley.
In this role, DeLorenzo will lead global corporate affairs,
including public affairs, government affairs, communications,
policy, advocacy, and stakeholder engagement. In addition,
DeLorenzo's role will concentrate on sharing and shaping the
company's overall global impact, including Environmental, Social
and Governance (ESG) and sustainability programs.
"Nina's extensive corporate affairs and leadership experience
will enable our company to create positive change for patients,
stakeholders, and the communities we serve during one of the
largest and most urgent public health emergencies of our time,"
said Chief Executive Officer Mark
Crossley. "To change outcomes for people struggling with
addiction and mental illness, we must partner across the treatment
spectrum to destigmatize, normalize, and enable equitable access to
treatment to help more people on the path to long-term recovery.
Nina's role is central to this mission."
DeLorenzo brings over two decades of public affairs,
communications, policy, and government affairs experience to
Indivior. Previously, DeLorenzo was senior vice president of global
communications and public affairs for Emergent BioSolutions.
DeLorenzo has also overseen external affairs operations and
engagement at Sanofi in Paris; led
global government affairs and public policy functions at AbbVie;
and held senior government and public affairs roles at Pfizer Inc.,
Schering-Plough Corp. (now Merck), and the Pharmaceutical Research
and Manufacturers of America (PhRMA).
"Indivior is committed to helping improve the lives of patients,
families, and communities," said DeLorenzo. "It's a privilege to
lead the team that will tell Indivior's story and work to change
outcomes for people struggling with stigmatized and socially
marginalized diseases."
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United
States in Richmond, VA, Indivior employs more than 900
individuals globally and its portfolio of products is available in
over 40 countries worldwide. Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Logo -
https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg